And an expanded market awaits its colorectal cancer blood test, though Exact will benefit first.
The quest for the Grail is beset with challenges.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
Setting its sights on the screening setting, Exact aims to be a major liquid biopsy player.
Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The first pan-cancer approval might have gone to Guardant, but Roche’s subsidiary’s blood test appears to be able to find more markers.
The liquid biopsy era is finally here.